
Infinimmune lands $75M Series A to push eczema antibodies forward
Biotech startup Infinimmune raises $75 million in a Series A led by Regeneron Ventures (with Playground Global) to advance its human B cell–based antibody platform for eczema, including lead antibodies IFX-201 and IFX-101 moving to Phase 1 next year. Regeneron’s investment aims to complement Dupixent, Merck remains an investor, and the company envisions additional large‑pharma partnerships as it advances its pipeline.

